A detailed history of Ubs Asset Management Americas Inc transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 94,795 shares of SRRK stock, worth $4.32 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
94,795
Previous 88,526 7.08%
Holding current value
$4.32 Million
Previous $737,000 2.99%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$7.63 - $9.71 $47,832 - $60,871
6,269 Added 7.08%
94,795 $759,000
Q2 2024

Aug 13, 2024

BUY
$7.84 - $16.79 $218,790 - $468,558
27,907 Added 46.04%
88,526 $737,000
Q1 2024

May 15, 2024

BUY
$13.2 - $17.76 $50,701 - $68,216
3,841 Added 6.76%
60,619 $1.08 Million
Q4 2023

Feb 14, 2024

BUY
$6.52 - $20.32 $35,051 - $109,240
5,376 Added 10.46%
56,778 $1.07 Million
Q3 2023

Nov 13, 2023

BUY
$6.02 - $7.76 $60,892 - $78,492
10,115 Added 24.5%
51,402 $364,000
Q1 2023

May 15, 2023

BUY
$7.36 - $12.72 $40,538 - $70,061
5,508 Added 15.39%
41,287 $330,000
Q4 2022

Feb 14, 2023

BUY
$7.02 - $9.76 $141,417 - $196,615
20,145 Added 128.85%
35,779 $323,000
Q1 2022

May 16, 2022

SELL
$11.89 - $24.68 $109,851 - $228,018
-9,239 Reduced 37.14%
15,634 $201,000
Q4 2021

Feb 14, 2022

BUY
$24.14 - $35.18 $196,354 - $286,154
8,134 Added 48.59%
24,873 $617,000
Q2 2021

Aug 16, 2021

BUY
$26.34 - $46.62 $39,668 - $70,209
1,506 Added 9.89%
16,739 $483,000
Q1 2021

May 14, 2021

SELL
$45.96 - $68.02 $59,610 - $88,221
-1,297 Reduced 7.85%
15,233 $771,000
Q4 2020

Mar 01, 2021

BUY
$13.72 - $51.57 $56,252 - $211,437
4,100 Added 32.98%
16,530 $802,000
Q3 2020

Nov 13, 2020

BUY
$10.54 - $18.47 $131,012 - $229,582
12,430 New
12,430 $219,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $2.35B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.